Trials / Completed
CompletedNCT04402840
Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- West Virginia University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 infection.
Detailed description
Primary Aim: • To determine safety of stellate ganglion block (SGB) in ARDS Secondary Aim: * To determine efficacy of SGB in slowing the progression of ARDS
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Stellate Ganglion Block | The procedure will be done at the bedside in the ICU without interfering with ongoing treatment. |
Timeline
- Start date
- 2020-04-24
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
- First posted
- 2020-05-27
- Last updated
- 2025-04-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04402840. Inclusion in this directory is not an endorsement.